StockNews.com upgraded shares of Ultralife (NASDAQ:ULBI - Free Report) from a hold rating to a buy rating in a report issued on Monday morning.
Ultralife Stock Down 3.2%
Shares of ULBI stock traded down $0.19 on Monday, reaching $5.73. 77,184 shares of the stock were exchanged, compared to its average volume of 69,934. The company has a current ratio of 3.30, a quick ratio of 1.62 and a debt-to-equity ratio of 0.04. The business's 50 day moving average price is $4.92 and its 200 day moving average price is $6.60. The company has a market capitalization of $95.31 million, a price-to-earnings ratio of 10.42 and a beta of 0.77. Ultralife has a twelve month low of $4.07 and a twelve month high of $12.40.
Ultralife (NASDAQ:ULBI - Get Free Report) last issued its earnings results on Friday, May 9th. The technology company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.02). Ultralife had a return on equity of 7.92% and a net margin of 5.44%. The firm had revenue of $50.75 million for the quarter, compared to analyst estimates of $54.50 million. During the same quarter in the previous year, the firm posted $0.21 EPS.
Insider Activity at Ultralife
In other Ultralife news, Director Bradford T. Whitmore bought 8,957 shares of Ultralife stock in a transaction dated Tuesday, May 13th. The stock was acquired at an average cost of $5.40 per share, with a total value of $48,367.80. Following the completion of the acquisition, the director now owns 1,029,884 shares of the company's stock, valued at approximately $5,561,373.60. This represents a 0.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas Louis Saeli bought 5,000 shares of Ultralife stock in a transaction dated Wednesday, May 14th. The stock was acquired at an average cost of $5.44 per share, with a total value of $27,200.00. Following the completion of the acquisition, the director now directly owns 85,000 shares of the company's stock, valued at approximately $462,400. The trade was a 6.25% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 35,160 shares of company stock valued at $191,543 over the last ninety days. Insiders own 39.90% of the company's stock.
Institutional Investors Weigh In On Ultralife
A number of institutional investors and hedge funds have recently made changes to their positions in ULBI. IFP Advisors Inc raised its holdings in shares of Ultralife by 24.6% in the first quarter. IFP Advisors Inc now owns 14,200 shares of the technology company's stock valued at $76,000 after buying an additional 2,800 shares during the last quarter. Jones Financial Companies Lllp increased its position in Ultralife by 1,428.7% during the 1st quarter. Jones Financial Companies Lllp now owns 15,287 shares of the technology company's stock worth $82,000 after purchasing an additional 14,287 shares during the period. Bank of America Corp DE increased its position in Ultralife by 30.7% during the 4th quarter. Bank of America Corp DE now owns 12,067 shares of the technology company's stock worth $90,000 after purchasing an additional 2,836 shares during the period. Barclays PLC increased its position in Ultralife by 13.7% during the 4th quarter. Barclays PLC now owns 15,233 shares of the technology company's stock worth $113,000 after purchasing an additional 1,838 shares during the period. Finally, Pitti Group Wealth Management LLC increased its position in Ultralife by 23.4% during the 1st quarter. Pitti Group Wealth Management LLC now owns 21,120 shares of the technology company's stock worth $114,000 after purchasing an additional 4,000 shares during the period. 30.68% of the stock is owned by hedge funds and other institutional investors.
Ultralife Company Profile
(
Get Free Report)
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
Featured Articles
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.